Apimeds Pharmaceuticals US, Inc. (APUS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Apimeds Pharmaceuticals US, Inc. (APUS) has a cash flow conversion efficiency ratio of -0.212x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.73 Million) by net assets ($8.16 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Apimeds Pharmaceuticals US, Inc. - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how Apimeds Pharmaceuticals US, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of Apimeds Pharmaceuticals US, Inc. for a breakdown of total debt and financial obligations.
Apimeds Pharmaceuticals US, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Apimeds Pharmaceuticals US, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Lead Real Estate Co., Ltd American Depositary Shares
NASDAQ:LRE
|
94.590x |
|
Rodrigo Tekstil Sanayi ve Ticaret AS
IS:RODRG
|
0.051x |
|
Smartlink Holdings Limited
NSE:SMARTLINK
|
0.022x |
|
Tectona
TA:TECT
|
-0.085x |
|
HK Co. Ltd
KQ:044780
|
0.021x |
|
Herald Investment Trust
LSE:HRI
|
0.046x |
|
RNI Negócios Imobiliários S.A
SA:RDNI3
|
-0.026x |
|
ADX Energy Ltd
AU:ADX
|
-0.118x |
Annual Cash Flow Conversion Efficiency for Apimeds Pharmaceuticals US, Inc. (2021–2024)
The table below shows the annual cash flow conversion efficiency of Apimeds Pharmaceuticals US, Inc. from 2021 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Apimeds Pharmaceuticals US, Inc..
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-1.36 Million | $-733.53K | 0.540x | +102.74% |
| 2023-12-31 | $31.87K | $-627.79K | -19.698x | -3236.44% |
| 2022-12-31 | $-713.61K | $-448.17K | 0.628x | -81.80% |
| 2021-12-31 | $-238.48K | $-823.11K | 3.451x | -- |
About Apimeds Pharmaceuticals US, Inc.
Apimeds Pharmaceuticals US, Inc. provides digital asset treasury solutions in bitcoin treasury infrastructure. The company is based in Ras al-Khaimah, the United Arab Emirates. Apimeds Pharmaceuticals US, Inc. operates as a subsidiary of Inscobee., Inc.